abs92.txt	uterine	serous	carcinoma	(usc)	represents	an	aggressive	histologic	subtype	ofendometrial	cancer		it	is	associated	with	a	poor	prognosis		and	improvedtherapies	for	women	battling	uscs	are	greatly	needed		onc201	is	an	orallybioavailable		first-in-class	small	molecule	that	induces	tumor	necrosisfactor-related	apoptosis-inducing	ligand	(trail)	independent	of	p53		onc201	hasdemonstrated	anti-tumorigenic	activity	in	pre-clinical	models	of	solid	tumorsthrough	induction	of	apoptosis	and	inactivation	of	the	akt/mapk	pathways		recentphase	i	and	ii	clinical	trials	have	shown	that	onc201	is	well	tolerated	and	mayhave	single	agent	activity	in	high	grade	glioma	patients	among	others		we	soughtto	determine	the	effects	of	onc201	on	cell	proliferation	in	usc	and	identify	themechanisms	by	which	onc201	inhibits	cell	growth	in	this	disease		onc201	inhibitedcell	proliferation	in	a	dose-dependent	manner	in	ark1		ark2	and	spec-2	celllines		the	anti-proliferative	activity	of	onc201	in	ark1	and	spec-2	cells	wasassociated	with	induction	apoptosis	independent	of	p53	via	both	a	trail	mediatedapoptotic	pathway	and	a	mitochondrial	apoptosis	pathway		treatment	with	onc201resulted	in	significant	reduction	in	adhesion	and	invasion	as	well	as	inhibitionof	the	akt	and	mapk	pathways		in	addition		onc201	markedly	potentiated	theanti-tumorigenic	effects	of	paclitaxel	in	usc	cells		our	results	suggest	thatonc201	has	significant	anti-proliferative	and	anti-metastatic	effects	in	usccells	through	both	induction	of	apoptosis	and	inhibition	of	the	akt	and	mapkpathways		onc201	and	paclitaxel	are	a	promising	therapeutic	combination	in	usccells		thus		onc201	should	be	evaluated	as	a	single	agent	and	as	a	therapeuticpartner	with	paclitaxel	in	future	clinical	trials	of	usc	
